PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Stemmer, K. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Müller, T.D.

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Adv. Drug Deliv. Rev. 159, 34-53 (2020)
Postprint DOI
Open Access Green
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
13.300
3.732
5
13
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Diabetes ; Dyslipidemia ; Incretins ; Lipoproteins ; Obesity; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Dependent Insulinotropic Polypeptide; Lipoprotein-lipase Activity; Low-density-lipoprotein; Dipeptidyl Peptidase-4 Inhibitor; Impaired Glucose-tolerance; Brown Adipose-tissue; High-fat; Receptor Agonist
Language english
Publication Year 2020
HGF-reported in Year 2020
ISSN (print) / ISBN 0169-409X
e-ISSN 1872-8294
Journal Advanced Drug Delivery Reviews
Quellenangaben Volume: 159, Issue: , Pages: 34-53 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-221
G-502200-001
Grants German Center for Diabetes Research (DZD e.V.)
Helmholtz Alliance ICEMED
Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association
Helmholtz cross-program topic "Metabolic Dysfunction"
German Research Foundation Grants
European Research Council ERC AdG HypoFlam
Alexander von Humboldt Foundation
DOI 10.1016/j.addr.2020.05.008
WOS ID WOS:000600557400004
Scopus ID 85086358886
Erfassungsdatum 2020-06-23
[➜Report correction]